Search tips
Search criteria 


Logo of procrsmedFormerly medchtJournal of the Royal Society of MedicineProceedings of the Royal Society of Medicine
Proc R Soc Med. 1963 May; 56(5): 414–418.
PMCID: PMC1897483

Symposium on Fibrinolysis

Full text

Full text is available as a scanned copy of the original print version. Get a printable copy (PDF file) of the complete article (889K), or click on a page image below to browse page by page. Links to PubMed are also available for Selected References.

Selected References

These references are in PubMed. This may not be the complete list of references from this article.
  • ABLONDI FB, HAGAN JJ. Comparison of certain properties of human plasminogen and proactivator. Proc Soc Exp Biol Med. 1957 Jun;95(2):195–200. [PubMed]
  • ALBRECHTSEN OK. The fibrinolytic activity of human tissues. Br J Haematol. 1957 Jul;3(3):284–291. [PubMed]
  • ALKJAERSIG N, FLETCHER AP, SHERRY S. The mechanism of clot dissolution by plasmin. J Clin Invest. 1959 Jul;38(7):1086–1095. [PMC free article] [PubMed]
  • AMBRUS JL, AMBRUS CM, BACK N, SOKAL JE, COLLINS GL. Clinical and experimental studies on fibrinolytic enzymes. Ann N Y Acad Sci. 1957 Aug 30;68(1):97–137. [PubMed]
  • BANG NU, FLETCHER AP, ALKJAERSIG N, SHERRY S. Pathogenesis of the coagulation defect developing during pathological plasma proteolytic ("fibrinolytic") states. III. Demonstration of abnormal clot structure by electron microscopy. J Clin Invest. 1962 Apr;41:935–948. [PMC free article] [PubMed]
  • BJERREHUUS I. Fibrinolytic activity of urine. Scand J Clin Lab Invest. 1952;4(3):179–182. [PubMed]
  • FEARNLEY GR, CHAKRABARTI R. Increase of blood fibrinolytic activity by testosterone. Lancet. 1962 Jul 21;2(7247):128–132. [PubMed]
  • FEARNLEY GR, CHAKRABARTI R, VINCENT CT. Effect of the sulphonylureas on fibrinolysis. Lancet. 1960 Sep 17;2(7151):622–625. [PubMed]
  • FLETCHER AP, ALKJAERSIG N, SHERRY S. Pathogenesis of the coagulation defect developing during pathological plasma proteolytic ("fibrinolytic") states. I. The significance of fibrinogen proteolysis and circulating fibrinogen breakdown products. J Clin Invest. 1962 Apr;41:896–916. [PMC free article] [PubMed]
  • FLETCHER AP, SHERRY S, ALKJAERSIG N, SMYRNIOTIS FE, JICK S. The maintenance of a sustained thrombolytic state in man. II. Clinical observations on patients with myocardial infarction and other thromboembolic disorders. J Clin Invest. 1959 Jul;38(7):1111–1119. [PMC free article] [PubMed]
  • JOHNSON AJ, TILLETT WS. The lysis in rabbits of intravascular blood clots by the streptococcal fibrinolytic system (streptokinase). J Exp Med. 1952 May 1;95(5):449–464. [PMC free article] [PubMed]
  • JOHNSON AJ, McCARTY WR. The lysis of artificially induced intravascular clots in man by intravenous infusions of streptokinase. J Clin Invest. 1959 Sep;38:1627–1643. [PMC free article] [PubMed]
  • KARDESCH M, HOGANCAMP CE, BING RJ. The survival of excitability, energy production and energy utilization of the heart. Circulation. 1958 Nov;18(5):935–945. [PubMed]
  • VON KAULLA KN. Intravenous protein-free pyrogen; a powerful fibrinolytic agent in man. Circulation. 1958 Feb;17(2):187–198. [PubMed]
  • VON KAULLA KN, SWAN H. Clotting deviations in man during cardiac bypass: fibrinolysis and circulating anticoagulant. J Thorac Surg. 1958 Oct;36(4):519–530. [PubMed]
  • KWAAN HC, MCFADZEAN AJ, COOK J. Plasma fibrinolytic activity in cirrhosis of the liver. Lancet. 1956 Jan 21;270(6908):132–136. [PubMed]
  • MCNICOL GP, DOUGLAS AS, BAYLEY C. Experience with streptokinase infusions. Lancet. 1962 Dec 22;2(7269):1297–1302. [PubMed]
  • MCNICOL GP, GALE SB, DOUGLAS AS. In-vitro and in-vivo studies of a preparation of urokinase. Br Med J. 1963 Apr 6;1(5335):909–915. [PMC free article] [PubMed]
  • NORMAN PS, HILL BM. Studies of the plasmin system. III. Physical properties of the two plasmin inhibitors in plasma. J Exp Med. 1958 Nov 1;108(5):639–649. [PMC free article] [PubMed]
  • NYDICK I, RUEGSEGGER P, BOUVIER C, HUTTER RV, ABARQUEZ R, CLIFFTON EE, LADUE JS. Salvage of heart muscle by fibrinolytic therapy after experimental coronary occlusion. Am Heart J. 1961 Jan;61:93–100. [PubMed]
  • RATNOFF OD. Studies on a proteolytic enzyme in human plasma. IX. Fibrinogen and fibrin as substrates for the proteolytic enzyme of plasma. J Clin Invest. 1953 Jun;32(6):473–479. [PMC free article] [PubMed]
  • SAWYER WD, FLETCHER AP, ALKJAERSIN N, SHERRY S. Studies on the thrombolytic activity of human plasma. J Clin Invest. 1960 Feb;39:426–434. [PMC free article] [PubMed]
  • SHERRY S, FLETCHER AP, ALKJAERSIG N. Fibrinolysis and fibrinolytic activity in man. Physiol Rev. 1959 Apr;39(2):343–382. [PubMed]
  • SHERRY S, LINDEMEYER RI, FLETCHER AP, ALKJAERSIG N. Studies on enhanced fibrinolytic activity in man. J Clin Invest. 1959 May;38(5):810–822. [PMC free article] [PubMed]
  • SHERRY S, TITCHENER A, GOTTESMAN L, WASSERMAN P, TROLL W. The enzymatic dissolution of experimental arterial thrombi in the dog by trypsin, chymotrypsin and plasminogen activators. J Clin Invest. 1954 Oct;33(10):1303–1313. [PMC free article] [PubMed]
  • TODD AS. The histological localisation of fibrinolysin activator. J Pathol Bacteriol. 1959 Jul;78:281–283. [PubMed]
  • WEBB WR, HOWARD HS. Extension of the limits of cardiac viability with total coronary occlusion. Surgery. 1957 Jul;42(1):92–100. [PubMed]
  • WEINER M, DE CRINIS K, REDISCH W, STEELE JM. Influence of some vasoactive drugs on fibrinolytic activity. Circulation. 1959 Jun;19(6):845–848. [PubMed]

Articles from Proceedings of the Royal Society of Medicine are provided here courtesy of Royal Society of Medicine Press